The industry has unlocked enormous microbiome potential but translating that science into consistent product performance remains a challenge. IFF Health Sciences breakfast briefing will frame the disconnect between promise and performance and set the stage for deeper discussion on how the next phase of probiotics will be defined by execution, not just innovation.